Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Noninvasive positive pressure ventilation

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    16 result(s) found for: Noninvasive positive pressure ventilation. Displaying page 1 of 1.
    EudraCT Number: 2016-002427-28 Sponsor Protocol Number: CIT-003-01 Start Date*: 2018-10-24
    Sponsor Name:Asklepion Pharmaceuticals, LLC
    Full Title: A Phase III Double-Blind, Randomized, Placebo Controlled, Multi-Center Clinical Study to Evaluate the Efficacy and Safety of Intravenous L-citrulline for the Prevention of Clinical Sequelae of Acut...
    Medical condition: Post-operative pulmonary dysfunction induced by cardiopulmonary bypass in pediatric subjects undergoing surgery for congenital heart defects.
    Disease:
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-003770-50 Sponsor Protocol Number: 20200403 Start Date*: 2021-10-13
    Sponsor Name:Všeobecná fakultní nemocnice v Praze
    Full Title: An Open-Label, Single/Multiple Ascending Dose Study to Assess the Pharmacokinetics, Efficacy, Safety and Tolerability of Inhalation Delivery of Hydroxychloroquine Sulfate (HCQ) in Healthy Volunteer...
    Medical condition: Healthy volunteers and patients with COVID - 19
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004862 10084510 Coronavirus infections HLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-005901-23 Sponsor Protocol Number: 1552/07 Start Date*: 2007-12-15
    Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
    Full Title: Prospective,Double-Blind Randomized Clinical Trial on the Effects of Early Administration of Prolonged Methylprednisolone Therapy in early Acute Lung Injury (ALI) and Acute Respiratory Distress Syn...
    Medical condition: Acute Lung Injury (ALI) - Acute Respiratory Distress Syndrome (ARDS)
    Disease: Version SOC Term Classification Code Term Level
    6.1 10049874 PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-001996-33 Sponsor Protocol Number: CD12_COVID-19 Start Date*: 2020-08-26
    Sponsor Name:CytoDyn, Inc.
    Full Title: A Phase 2b/3, Randomized, Double Blind, Placebo Controlled, Adaptive Design Study to Evaluate the Efficacy and Safety of Leronlimab for Patients with Severe or Critical Coronavirus Disease 2019 (CO...
    Medical condition: Coronavirus Disease 2019 (COVID-19)
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004862 10053983 Corona virus infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2017-001768-39 Sponsor Protocol Number: SURFABRON Start Date*: 2018-03-07
    Sponsor Name:AZIENDA OSPEDALIERA UNIVERSITARIA INTEGRATA VERONA
    Full Title: Randomized multicentre-controlled, placebo-controlled (1: 1) study to evaluate the efficacy and safety of Curosurf in patients under 12 months of age with moderate or severe acute respiratory distr...
    Medical condition: Acute severe hypoxic bronchiolitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10000686 Acute bronchiolitis LLT
    Population Age: Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-002259-39 Sponsor Protocol Number: TL-895-202 Start Date*: 2020-09-23
    Sponsor Name:Telios Pharma, Inc.
    Full Title: A Phase 1/2, Double-Blind, Randomized, Placebo-Controlled Study of TL-895 with Standard Available Treatment versus Standard Available Treatment for the Treatment of COVID-19 in Patients with Cancer
    Medical condition: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in patients with cancer
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004862 10084270 SARS-CoV-2 acute respiratory disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: RO (Prematurely Ended) HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-001194-24 Sponsor Protocol Number: V3011902 Start Date*: 2021-12-15
    Sponsor Name:Veru Inc.
    Full Title: Phase 3, Randomized, Placebo-Controlled, Efficacy and Safety Study of VERU-111 for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Patients at High Risk for Acute R...
    Medical condition: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Patients at High Risk for Acute Respiratory Distress Syndrome (ARDS)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10021881 - Infections and infestations 10035737 Pneumonia viral PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: View results
    EudraCT Number: 2020-001497-30 Sponsor Protocol Number: ALXN1210-COV-305 Start Date*: 2020-05-07
    Sponsor Name:Alexion Pharmaceuticals, Inc.
    Full Title: COVID-19 A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-1...
    Medical condition: COVID-19 severe pneumonia, acute lung injury, or acute respiratory distress syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10061229 Lung infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-000876-27 Sponsor Protocol Number: ATX-MTM-002 Start Date*: 2017-12-06
    Sponsor Name:Audentes Therapeutics Inc.
    Full Title: ASPIRO: A Phase 1/2, Randomized, Open-Label, Ascending-Dose, Delayed-Treatment Concurrent Control Clinical Study to Evaluate the Safety and Efficacy of AT132, an AAV8-Delivered Gene Therapy in X-L...
    Medical condition: X-linked Myotubular Myopathy (XLMTM)
    Disease:
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Trial now transitioned) FR (Trial now transitioned)
    Trial results: View results
    EudraCT Number: 2020-002369-32 Sponsor Protocol Number: 100-303 Start Date*: 2020-07-31
    Sponsor Name:Diffusion Pharmaceuticals Inc.
    Full Title: Open-label, pharmacokinetic, pharmacodynamic, ascending dose safety lead-in followed by a single-center, placebo-controlled, double-blind, adaptive, safety and efficacy, pilot study of Trans Sodium...
    Medical condition: COVID-19 infection
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004862 10084401 COVID-19 respiratory infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: RO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-001644-25 Sponsor Protocol Number: ACE-ID-201/D822FC00001 Start Date*: 2020-05-06
    Sponsor Name:Acerta Pharma B.V.
    Full Title: A Phase 2 Randomized Study of the Efficacy and Safety of Acalabrutinib with Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized with COVID-19
    Medical condition: Subjects with life-threatening COVID-19 symptoms
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10051905 Coronavirus infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) ES (Completed) SE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-001577-70 Sponsor Protocol Number: RESCAT Start Date*: 2020-12-28
    Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA DI MODENA
    Full Title: Allogeneic Mesenchymal Stromal Cell (MSC) Therapy for SARS-CoV-2 Pneumonia: A Prospective Randomized Multicentre Phase I/IIa Open Label Study
    Medical condition: SARS-CoV-2 pneumonia
    Disease: Version SOC Term Classification Code Term Level
    22.1 100000004862 10061229 Lung infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-001696-22 Sponsor Protocol Number: 64041575MPN2001 Start Date*: 2018-06-28
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 2b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered Lumicitabine ...
    Medical condition: Human metapneumovirus infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10066226 Metapneumovirus infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Temporarily Halted) PL (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-001393-16 Sponsor Protocol Number: SHP607-202 Start Date*: 2019-06-21
    Sponsor Name:Premacure AB
    Full Title: A Phase 2b, Multicenter, Randomized, Open-label, Controlled, 3-Arm Study to Evaluate the Clinical Efficacy and Safety of SHP607 in Preventing Chronic Lung Disease Through 12 Months Corrected Age Co...
    Medical condition: Chronic Lung Disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10066204 Chronic lung disease of prematurity LLT
    Population Age: Preterm newborn infants, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IE (Trial now transitioned) SE (Prematurely Ended) FR (Completed) DE (Trial now transitioned) PT (Trial now transitioned) ES (Temporarily Halted) FI (Trial now transitioned) NL (Trial now transitioned) PL (Prematurely Ended) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-003157-27 Sponsor Protocol Number: Sobi.PEGCET-201 Start Date*: 2021-12-17
    Sponsor Name:SWEDISH ORPHAN BIOVITRUM AB (PUBL)
    Full Title: An Open-label, Single-arm, Multicenter Pilot Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Pegcetacoplan in Patients with Transplant-associated Thrombotic Microangiopathy (...
    Medical condition: Transplant-Associated Thrombotic Microangiopathy (TA-TMA)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10043645 Thrombotic microangiopathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned) FR (Trial now transitioned) GR (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-001641-79 Sponsor Protocol Number: 64041575RSV2001(ALS-8176-505) Start Date*: Information not available in EudraCT
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 2b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, Viral Kinetics, and Pharmacokinetics of Orally Administer...
    Medical condition: Respiratory Syncytial Virus Infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10061603 Respiratory syncytial virus infection PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 11 09:39:10 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA